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ABSTRACT 
Probiotic formulations must include a high number of viable and active microorganisms. In 
this work, the survival of human vaginal Lactobacillus reuteri CRL 1324 during 
encapsulation, lyophilization and storage, and the activity of encapsulated and/or freeze-dried 
bacterial cells were evaluated. Extrusion-ionic gelation technique was applied to encapsulate 
L. reuteri CRL 1324, using xanthan and gellan. Encapsulated and free bacterial cells were 
freeze-dried with or without lactose and skim milk as lyoprotectors. The different systems 
obtained were stored at room temperature and at 4°C for 150 days. The following 
determinations were performed: L. reuteri CRL 1324 viability, microorganism released from 
capsules, survival in a medium simulating the vaginal fluid and maintenance of beneficial 
properties (growth inhibition of opportunistic pathogenic Streptococcus agalactiae NH 17 and 
biofilm formation). L. reuteri CRL 1324 encapsulation was efficient, allowing the recovery of 
a high number of entrapped lactobacilli. The survival of encapsulated L. reuteri during 
lyophilization and storage was significantly higher in the presence of lyoprotectors. At the end 
of storage, highest numbers of viable cells were obtained in free or encapsulated cells freeze-
dried with lyoprotectors, stored at 4°C. Encapsulated and/or liophilized L. reuteri cells 
maintained their viability in simulated vaginal fluid as well as the ability to inhibit S. 
agalactiae NH 17 growth and to form biofilm. Encapsulated and freeze-dried L. reuteri CRL 
1324 can be included in a suitable pharmaceutical form for vaginal application to prevent or 
treat urogenital infections in women. 
 
Key words: Vaginal probiotic, encapsulation, freeze-drying, storage, activity maintenance, 
simulated vaginal fluid survival 
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1. Introduction 
Female urogenital tract infections affect one billion people worldwide each year (Reid, 
2014). Conventional treatments with different drugs have failed to restore the normal vaginal 
microbiome, which is dominated by lactobacilli (Human Microbiome Project Consortium, 
2012; Witkin, 2015). Therefore, the use of probiotics containing beneficial lactobacilli is a 
promising alternative to prevent or treat urogenital tract infections (Reid, 2014). Probiotics are 
defined as live microorganisms that, when administered in adequate amounts, confer a health 
benefit on the host (FAO/WHO, 2001; Hill et al., 2014).  
The effectiveness of probiotics depends on the number of viable cells, being 10
7
 and 
10
9
 colony forming units (CFU) the recommended amount per dose of formulation (Ding and 
Shah, 2009; Mastromarino et al., 2013; Hill et al., 2014). Therefore, during the design of 
probiotic products, the main technological requirement is the microbial stability during the 
processes of biomass production (to include the required number of viable and active 
microorganisms in the final product) and during the shelf life period (du Toit et al., 2013; 
Domig et al., 2014; Hill et al., 2014).  
Freeze-drying and encapsulation are methods widely applied to preserve and protect 
microbial viability (Pliszczak et al., 2011; Muller et al., 2013). Encapsulation protects the 
active ingredients against stressing physical-chemical factors such as heat, humidity, extreme 
pH, harmful substances, etc. (Islam et al., 2010; Solanki et al., 2013). This process could 
favor an increase in microbial stability in the conditions of the ecological niche in which the 
microorganisms will be applied. On the other hand, this technology can support a controlled 
release and a reduction in the irritant effect of certain active pharmaceutical ingredients 
(Remuñán López and Alonso Fernández, 1997). 
In vaginal probiotic products, the microorganisms must be included in matrixes with 
low water activity (Pliszczak et al., 2011). However, the preservation processes applied to 
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microbial cells can cause structural and physiological cell damage by several mechanisms, 
leading to decrease of viability (Weinbreck et al., 2010; du Toit et al., 2013). Freeze-drying of 
beneficial lactic acid bacteria strains has been proved successful to preserve bacterial stability 
during the elaboration of various pharmaceutical forms for vaginal application and during 
storage for different time periods (Borges et al., 2013; Muller et al., 2013, 2014; Verdenelli et 
al., 2014). However, to the best of our knowledge, the stability (viability and activity) of 
vaginal probiotic strains during encapsulation and freeze-drying and their subsequent storage 
has not yet been reported. 
In previous studies, vaginal Lactobacillus reuteri CRL 1324 was selected as a 
candidate probiotic for its potential beneficial properties. This microorganism inhibits the 
growth of urogenital pathogenic Streptococcus agalactiae, Enterococcus faecalis, 
Enterococcus sp., Escherichia coli, Staphylococcus aureus, Klebsiella sp., Neisseria 
gonorrhoeae and Garnerella vaginalis strains, shows high auto-aggregative and mucin-
adhesive capacity, forms biofilm under different culture conditions, co-aggregates with S. 
agalactiae and S. aureus, exerts a preventive effect against vaginal colonization by S. 
agalactiae in a murine experimental model and survives in conditions simulating the vaginal 
fluid (Juárez Tomás et al., 2003, 2011; Leccese Terraf et al., 2012, 2014; De Gregorio et al., 
2014, 2015). The aim of this work was to evaluate the stability (viability and maintenance of 
beneficial properties) of L. reuteri CRL 1324 during encapsulation, freeze-drying and storage 
under different conditions.  
 
2. Materials and methods 
2.1. Microorganisms and culture conditions 
Biofilm-forming L. reuteri CRL (Centro de Referencia para Lactobacilos Culture 
Collection) 1324 was originally isolated from human vagina in Tucumán, Argentina. L. 
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reuteri CRL 1324 was obtained from subcultures of a single colony and its purity was 
checked by Gram staining and catalase test. Lactobacillus strain was stored in a milk-yeast 
extract (13% non-fat milk, 0.5% yeast extract and 1% glucose) at -20°C (Ocaña et al., 1999). 
Before experimental use, stored L. reuteri CRL 1324 was grown in De Man-Rogosa-Sharpe 
(MRS) broth (Merck, Germany) (De Man et al., 1960) at 37°C for 24 h under static conditions 
and subcultured in the same medium at 37°C for 12 h (second subculture) and then for 16 h 
(third subculture). 
For inhibition assays, opportunist pathogenic vaginal S. agalactiae NH 17 (previously 
isolated at the Nuevo Hospital „El Milagro‟, Salta, Argentina) was used as a sensible strain to 
L. reuteri CRL 1324 (De Gregorio et al., 2014). S. agalactiae NH 17 was cultured in LAPTg 
(yeast extract/peptone/tryptone/Tween 80/glucose) broth (Raibaud et al., 1973) at 37°C for 12 
h and then subcultured at 37°C in the same medium for 9 h up to 0.8 optical density at 600 nm 
(OD600 nm) (Spectronic 20, Bausch and Lomb, Rochester NY). 
 
2.2. Encapsulation of L. reuteri CRL 1324 
Bacterial cells from the third L. reuteri CRL 1324 broth subculture were centrifuged 
(6000 g for 10 min at 4°C), washed twice and resuspended in distilled water (to decrease the 
amount of ions interacting with encapsulating polymers), and a concentrated culture of around 
10
10
-10
11
 CFU/ml was obtained. 
Extrusion-ionic gelation was the encapsulation technique applied, according to the 
methodology described by Sun and Griffiths (2000) and Jiménez-Pranteda et al. (2012), with 
modifications. Before the encapsulation assay, 1% xanthan gum-0.75% gellan gum polymeric 
mixture (polymers from Sigma-Aldrich, St. Louis, Missouri, USA) was prepared. Adequate 
amounts of each polymer powder were dispersed in 15 ml of deionized preheated water 
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(80°C) by magnetic stirring and kept at 80°C until complete hydration of the polymeric 
mixture, which was autoclaved (for 15 min at 121°C) and stored at 4°C. 
Concentrated cultures of L. reuteri CRL 1324 were homogeneously resuspended in the 
xanthan-gellan polymeric mixture [1:15 (vol/vol) ratio]. The bacterial cells and polymers mix 
was extruded at a flow rate of 90 ml/h through a syringe pump (KDS Model 100 Series, KD 
Scientific, Inc., USA) equipped with a 10 ml syringe (BD, Belgium) connected to a needle 
(TIP 27 G x ½ in., BD, Belgium). The capsules were recovered and hardened in 0.1 M CaCl2 
for 30 min at 4°C (under gently magnetic stirring), washed with distilled water and separated 
by filtration (with a sterile funnel and filter paper). The material weight was determined and 
the encapsulation yield, defined as the percentage of capsule weight obtained with respect to 
the total weight of the material used (active ingredient -bacterial cells- and polymeric mixture) 
was calculated (Alli, 2011). 
 
2.3. Lyophilization of encapsulated cells and cell suspensions of L. reuteri CRL 1324 
Capsule aliquots containing L. reuteri were subjected to a subsequent freeze-drying 
process, resuspended or not in a lyoprotector solution containing 12% (wt/vol) lactose and 6% 
(wt/vol) reconstituted skim milk (lactose+skim milk) (Juárez Tomás et al., 2009). On the 
other hand, L. reuteri CRL 1324 free cells (concentrated cultures) were resuspended in 
lactose-skim milk [1:15 (vol/vol) ratio] and freeze-dried. The samples of capsules and L. 
reuteri CRL 1324 free cells were distributed in Petri dishes, frozen at 70°C for 24 h and dried 
in a chamber type freeze-drier (Lyovac GT2; Leybold, Köln, Germany) for 16 h at 0.3 mbar 
(1 bar = 100 kPa), which yielded products with <1% residual moisture. 
 
2.4. Storage conditions 
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The different systems (nonlyophilized capsules, freeze-dried capsules and freeze-dried 
free cells of L. reuteri CRL 1324) were dispensed aseptically into screw-capped vials. The 
vials were placed in sealed plastic containers (Parafilm® M, Wertheim, Germany) containing 
silica-gel desiccants and stored at room temperature and at refrigeration temperature (4°C) 
under dark conditions for 150 days. Fig. 1 summarizes the conditions of preparation and 
storage of the different systems assayed to preserve the stability of L. reuteri CRL 1324. 
 
2.5. Sampling and analytical procedures 
The amount of active ingredient (number of L. reuteri CRL 1324 viable cells) before 
and after encapsulation and freeze-drying processes and during storage (0, 21, 60 and 150 
days) was determined in samples of all the systems assayed. Survival rate during 
encapsulation or lyophilization was expressed as NAE/NBE or NAL/NBL, where NAE and NBE are 
the log CFU/g after encapsulation and before encapsulation, respectively, and NAL and NBL 
are the log CFU/g after lyophilization and before lyophilization, respectively (Martos et al., 
2007; Juárez Tomás et al., 2009). 
 
2.5.1. Determination of viable cells 
Nonlyophilized and lyophilized encapsulated bacterial cells were released by 
dissolving a weighed quantity of xanthan-gellan capsules in 0.05 M sodium phosphate buffer 
(g/l: NaH2PO4, 5.30; Na2HPO4.2H2O, 13.32; pH 7.0) and disaggregated with a Teflon pestle 
homogenizer for 1 min. Lyophilized capsules were previously rehydrated in 0.05 M sodium 
phosphate buffer for 10 min at room temperature. In the case of freeze-dried free cells, they 
were rehydrated in saline for 10 min at room temperature before viable cell counting. The 
number of L. reuteri CRL 1324 viable cells was determined from aliquots of each sample by 
the successive dilution method, using saline as dilution medium and MRS agar (MRS-1.5% 
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agar, pH 6.5) as culture medium. Plates were incubated under aerobic conditions at 37°C for 
48 h, and the number of CFU registered. 
 
2.5.2. Optical microscopy and scanning electronic microscopy of freeze-dried capsules  
The morphological characteristics and internal structure of some capsules (i.e. 
xanthan-gellan capsules lyophilized in presence of lactose-skim milk) containing L. reuteri 
CRL 1324 were analyzed by scanning electronic microscopy. Freeze-dried capsules were 
previously rehydrated in a medium simulating the vaginal fluid (MSVF, g/l composition: 
glucose, 10; lactic acid, 2; acetic acid, 1; albumin, 2; mucin, 0.25; urea, 0.50; NaCl, 3.5; KCl, 
1.5; cysteine, 0.50; 1 ml/l Tween 80; pH 4.25 ± 0.05) (Juárez Tomás and Nader-Macías, 
2007) for 10 min at room temperature.  
Samples were fixed with Karnovsky fixative [8% (wt/vol) paraformaldehyde in 
phosphate buffer; 16% (wt/vol) glutaraldehyde] overnight at 4°C. Fixed samples were washed 
three times with phosphate buffer for 10 min and treated overnight with 1:1 
osmium/phosphate buffer solution (2% OsO4). The osmium solution was later removed. The 
samples were washed twice with 30% ethanol for 10 min and then dehydrated through a 
series of increasing alcohol concentrations: 50, 70, 80, 90 and 100% ethanol three times, 10 
min each time. 100% ethanol was eliminated and 100% acetone added for 1 h. Later, the 
samples were mounted in an aluminum holder, covered with a gold layer by using a metallizer 
and observed with high vacuum in a Zeiss Supra 55VP (Carl Zeiss microscope, Oberkochen, 
Germany) scanning electron microscope. The size of freeze-dried capsules was determined 
from images acquired by optical microscopy (Axio A1 Carl Zeiss microscope, Oberkochen, 
Germany). The images were processed using the Axio-Vision Release 4.8 software. 
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2.5.3. Release of L. reuteri CRL 1324 from xanthan-gellan capsules. Survival of freeze-dried 
and encapsulated cells in genital tract conditions 
A weighed quantity of xanthan-gellan capsules (lyophilized in lactose-skim milk) was 
inoculated into tubes containing 2.5 ml MSVF (a tube for each time point) and incubated at 
37°C without agitation. Samples were taken at 3, 6, 9 and 24 h of incubation. Each sample 
was filtered to recover only cells in suspension (i.e. cells released into MSVF from capsules). 
The number of viable L. reuteri CRL 1324 cells released was determined by the successive 
dilution method in MRS agar plates, as described previously (item 2.5.1.). For each sampling 
time, the release rate was expressed as Nt/Ni, where Nt is the log CFU/g in incubation time 
“t” and Ni is the log CFU/g in the initial incubation time. 
On the other hand, for each sampling time, capsules retained in the filter were later 
transferred to 0.05 M sodium phosphate buffer (pH 7.0) and disaggregated with a 
homogenizer to release encapsulated cells mechanically, as described above. The number of 
L. reuteri CRL 1324 viable cells in the different samples was determined by the successive 
dilution method in MRS agar plates, as described previously (item 2.5.1.). The survival of 
encapsulated cells in MSVF was calculated considering the total number of viable cells (cells 
released into MSVF from capsules plus encapsulated cells that were mechanically released). 
The survival rate in MSVF was expressed as Nt/Ni, where Nt is the log CFU/g in incubation 
time “t” and Ni is the log CFU/g in the initial incubation time. 
 
2.5.4. Growth inhibition of opportunist pathogenic S. agalactiae NH 17 by L. reuteri CRL 
1324 
Associated cultures between S. agalactiae NH 17 and L. reuteri CRL 1324 [aliquots 
of disaggregated lyophilized in lactose-skim milk capsules, rehydrated freeze-dried free cells 
or fresh free cells (from the third subculture in MRS broth)] were performed in LAPTg broth 
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at 37°C under static conditions. A 1:100 ratio of initial viable cells between NH 17 and CRL 
1324 was assayed (De Gregorio et al., 2014). Pure cultures of each microorganism were 
grown under the same culture conditions as control. At 24 h of incubation, the number of 
viable cells was determined by the successive dilution method, using selective culture media: 
MRS agar (pH 5.5) for lactobacilli and Bacto Todd-Hewitt agar (pH 7.8) (Becton Dickinson) 
for streptococci (De Gregorio et al., 2014). The plates were incubated at 37°C for 48 h 
 
2.5.5. Formation of biofilm 
The ability of L. reuteri CRL 1324 to form biofilm in MRS without Tween 80 was 
previously demonstrated (Leccese Terraf et al., 2012). Aliquots of disaggregated capsules 
(lyophilized in lactose-skim milk) containing L. reuteri CRL 1324, rehydrated freeze-dried 
free cells or fresh free cells (from the third subculture in MRS broth) were incubated in 5 ml 
MRS broth without Tween 80 for 24 h at 37°C. After this incubation period, the inoculum for 
biofilm formation assay was prepared with bacterial pellets from each culture, washed and 
resuspended in saline up to an OD540nm of 1.5. The microplate assay was carried out according 
to the technique previously described (Leccese Terraf et al., 2012, 2014), always including  
sterile culture medium as negative control, and using crystal violet as stain and 30% acetic 
acid as stain eluent. OD570nm values (in Microplate Spectrophotometer, VERSAmax, 
Molecular Devices, Sunnyvale, CA, USA) were used to express biofilm formation 
quantitatively (Leccese Terraf et al., 2012).  
 
2.6. Statistical analysis 
Analysis of variance (ANOVA) using a general linear model was applied to determine 
the main and interaction effects of factors evaluated in each of the following processes: a) 
encapsulation: time of the encapsulation process (pre- and post-encapsulation); b) 
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lyophilization: time of the lyophilization process (pre- and post-lyophilization) and 
lyophilization condition (freeze-dried capsules in the presence or absence of lactose-skim 
milk and lyophilized free cells in lactose-skim milk); c) storage: system in which L. reuteri 
was stored (freeze-dried capsules in the presence or absence of lactose-skim milk, 
nonlyophilized capsules and lyophilized free cells in lactose-skim milk), temperature (room 
and refrigerated temperatures) and time (0, 21, 60 and 150 days). The number of L. reuteri 
CRL 1324 viable cells (log CFU/g) was the response of interest analyzed in the different 
processes. 
ANOVA using a general linear model was also applied to analyze: a) the effects of the 
condition in which L. reuteri was inoculated (cells included in lyophilized capsules in the 
presence of lactose-skim milk, lyophilized free cells in lactose-skim milk and fresh free cells) 
and incubation time (0, 3, 6, 9 and 24 h) on the survival rate in MSVF; b) the effects of the 
culture type (pure and associated) and condition in which L. reuteri was inoculated on the 
viability of S. agalactiae NH 17 and lactobacilli (log CFU/ml), in S. agalactiae NH 17 
inhibition assay; c) the effects of the condition in which L. reuteri was inoculated on biofilm 
formation (OD570 nm). 
In each analysis, significant differences (P < 0.05) between mean values were 
determined by Tukey‟s test, using MINITAB statistical software (version 16 for Windows). 
 
3. Results 
3.1. Encapsulation of L. reuteri CRL 1324 
When applying the extrusion-ionic gelation technique to encapsulate L. reuteri CRL 
1324 cells using xanthan-gellan, high encapsulation yield of capsules (72.5 ± 2.0 %) and high 
L. reuteri CRL 1324 survival rate during encapsulation (0.89 ± 0.02) were obtained. The 
number of viable cells before and after the encapsulation process was statistically different 
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(viability decrease = 1.15 ± 0.27 log units). However, a high number of encapsulated cells 
was obtained (log CFU/g capsules = 9.06 ± 0.27). 
 
3.2. Lyophilization of encapsulated and free cells of L. reuteri CRL 1324 
The survival of encapsulated and free cells of L. reuteri CRL 1324 during 
lyophilization was compared. Significant differences between L. reuteri CRL 1324 viability 
before and after the lyophilization process and between the different systems assayed were 
observed (Fig. 2). When encapsulated L. reuteri CRL 1324 was freeze-dried, survival was 
significantly higher in the presence of the lactose-skim milk protective mixture than in its 
absence. However, the viability decrease after the lyophilization of free bacterial cells with 
lactose-skim milk (0.75 ± 0.01 log CFU/g units) was significantly lower than that of 
encapsulated cells lyophilized either with or without lactose-skim milk (decrease of 3.17 ± 
0.12 or 4.07 ± 0.09 log CFU/g units, respectively). Therefore, the survival rate of free cells 
(0.92 ± 0.001) during lyophilization was higher than encapsulated cells (0.70 ± 0.01 or 0.62 ± 
0.01 with or without lactose-skim milk, respectively).  
 
3.3. Viability during storage of encapsulated and lyophilized L. reuteri CRL 1324 
The different factors assayed (system in which bacterial cells were stored, temperature 
and time) significantly affected the viability of L. reuteri CRL 1324 during storage (Fig. 3). 
System-temperature, system-time and temperature-time interaction effects were also 
significant (P < 0.05), indicating that the effect of each factor was dependent on the other 
factors considered. In general, the highest survival of L. reuteri CRL 1324 during storage was 
obtained from the systems (free and encapsulated cells) that were lyophilized with lactose-
skim milk. In all the systems assayed, bacterial viability was significantly higher after storage 
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at 4°C than at room temperature. On the other hand, a significant decrease in viability was 
observed at different storage times (Fig. 3).  
Based on the differences observed in L. reuteri CRL 1324 viability at the two storage 
temperatures, bacterial survival in different systems and storage times were analyzed for each 
temperature (Fig. 4a). At room temperature, highest L. reuteri survival was evidenced in 
lyophilized free cells. After 21 days of storage, no viable cells were recovered from 
nonlyophilized capsules or from freeze-dried capsules without lactose-skim milk. At day 60, 
no viable cells were obtained in freeze-dried capsules with lactose-skim milk. 
At refrigerated temperature, significant differences in L. reuteri CRL 1324 viability 
were evidenced between the different systems and between the storage times assayed (Fig. 
4b). After 150 storage days, the highest numbers of viable cells were obtained in freeze-dried, 
nonencapsulated cultures (4 x 10
8
 CFU/g) and in freeze-dried capsules with lactose-skim milk 
(1 x 10
6
 CFU/g). In these systems, bacterial viability did not decrease significantly during the 
storage period assayed. However, in lyophilized capsules without lyoprotectors, viability at 
day 150 was significantly lower than at days 0, 21 and 60. In this system, no viable cells were 
detected at day 21 of storage, in a similar way to the results obtained at room temperature. 
 
3.4. Characterization of xanthan-gellan capsules. Functional and beneficial properties of 
freeze-dried and/or encapsulated L. reuteri CRL 1324 
On the basis of the viability results obtained from the different encapsulated systems 
and storage conditions assayed, the xanthan-gellan capsules lyophilized with lactose-skim 
milk and stored at 4°C were selected for its characterization. In this system, a high number of 
viable cells was evidenced at the end of the storage period. Moreover, lyophilized free cells 
dried with lactose-skim milk and stored at 4°C were evaluated in most of the following 
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assays, since the highest recovery of L. reuteri CRL 1324 viable cells during storage was 
evidenced in this system. 
 
3.4.1. Morphology, size and internal structure of selected xanthan-gellan capsules 
Xanthan-gellan capsules lyophilized in the presence of lactose-skim milk were 
observed as imperfect spheres with an average diameter of 2.42 ± 0.47 mm. Scanning 
electronic microscopy analysis showed that the capsule surface was heterogeneous, with no 
evident pores or fractures (Fig. 5a-b). When analyzing the capsules inside, individual or 
aggregated bacterial cells included in the polymeric matrix were observed (Fig. 5c-d). 
 
3.4.2. Release of L. reuteri CRL 1324 from xanthan-gellan capsules into a medium simulating 
vaginal fluid 
L. reuteri CRL 1324 was markedly released in MSVF when included in xanthan-
gellan capsules during the first 3 h of incubation (Fig. 6a). At that time, the release rate was 
0.78 ± 0.01, corresponding to a difference of around one log unit between the total number of 
encapsulated microorganisms and the released number. The viable cells in suspension were 
similar between 3 and 24 h of incubation. 
 
3.4.3. Survival of freeze-dried and encapsulated cells in genital tract conditions  
For each system in which L. reuteri CRL 1324 was inoculated in MSVF, survival rates 
were not significantly different during 24 h of incubation at 37°C. On the other hand, at the 
end of incubation, the survival rate of bacteria from fresh cultures was significantly lower 
than that from lyophilized free cells (data not shown). However, no significant differences 
were observed in the survival rates of freeze-dried encapsulated bacteria and freeze-dried or 
control cultures.  
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3.4.4. Growth inhibition of S. agalactiae NH 17 by L. reuteri CRL 1324 
L. reuteri CRL 1324 cells from encapsulated and/or freeze-dried samples inhibited the 
growth of S. agalactiae NH 17 after 24 h of co-culture at 37°C in LAPTg broth. At this time, 
the number of NH 17 viable cells was significantly lower in CRL 1324-NH 17 associative 
cultures than in NH 17 pure cultures (Fig. 6b). There were no statistical differences in S. 
agalactiae NH 17 viability decrease (2.89 ± 0.13 log CFU/ml) between associative cultures 
that were inoculated with encapsulated, freeze-dried or control L. reuteri cells. The viability 
of L. reuteri CRL 1324 was similar in pure and mixed cultures under the different conditions 
assayed. 
 
3.4.5. Formation of biofilm 
Encapsulated and/or freeze-dried L. reuteri maintained the capability to form biofilm 
in MRS without Tween 80. No significant differences were observed in the biofilm formed 
(expressed as OD570 nm values) from freeze-dried encapsulated cells, freeze-dried free cells or 
control cells (Fig. 6c). 
 
4. Discussion 
Freeze-drying and microencapsulation are methods frequently applied in food and 
pharmaceutical industries to protect various compounds and microorganisms against different 
stressing physical-chemical factors (Solanki et al. 2013; Endo et al. 2014). Several studies on 
encapsulation of microorganisms with potential food application were carried out to protect 
them from adverse conditions in the gastrointestinal tract (Ding and Shah, 2009; Islam et al., 
2010; Weinbreck et al., 2010; Jiménez-Pranteda et al., 2012). Only a few works reported the 
encapsulation of potential probiotic microorganisms for the human urogenital tract (Martín 
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Villena et al., 2010; Pliszczak et al., 2011). These authors applied the emulsification-gelation 
method (using bioadhesive polymers) and assayed the survival of microorganisms during the 
encapsulation process but not during storage. 
Polymers of different chemical nature are commonly used to encapsulate 
microorganisms, e.g. alginate, pectin, hyaluronic acid (natural polysaccharides), xanthan, 
gellan and pullulan gums (microbial natural exopolysaccharides), hydroxypropyl 
methylcellulose (a semisynthetic cellulose derivative mucoadhesive) and polyethylene glycol 
(a synthetic polyether), among others (Ding and Shah, 2009; Martín Villena et al., 2009; Alli, 
2011, Pliszczak et al., 2011). In the pharmaceutical area, several polymers with mucoadhesive 
properties are applied to improve or increase the permanence time of the systems in the 
mucosa of interest (Pliszczak et al., 2011), of main importance by the localization of the 
vaginal tract in the human body.  
In the present work, encapsulation and freeze-drying methods were applied to preserve 
L. reuteri CRL 1324, a urogenital probiotic candidate strain selected for its beneficial 
properties. Xanthan and gellan gums were employed to encapsulate L. reuteri CRL 1324 on 
the basis of the results obtained in other studies, in which different Lactobacillus and 
Bifidobacterium strains (for products administered orally) were successfully encapsulated 
with the aforementioned polymers (Sun and Griffiths, 2000; Jiménez-Pranteda et al., 2012). 
Moreover, microbial natural exopolysaccharides, widely applied in foods, are safe for human 
use (Jiménez-Pranteda et al., 2012). L. reuteri CRL 1324 was efficiently encapsulated 
applying the extrusion-ionic gelation technique. A high number of viable cells were recovered 
(around 10
9
 CFU/g of capsules), indicating that this microorganism mantained its viability 
during the encapsulation process. 
The lyoprotective effect of several substances against stress by freeze-drying was 
widely reported (Santivarangkna et al., 2008; Savini et al., 2010). In previous studies 
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performed on the lyophilization of vaginal Lactobacillus free cells, the effects of lactose and 
sucrose suspended in water or reconstituted skim milk on the stability during freeze-drying 
and subsequent storage of vaginal lactobacilli strains were evaluated (Juárez Tomás et al., 
2009). Optimal stability results were obtained in the presence of lactose+skim milk (Juárez 
Tomás et al., 2009). Supported by the results obtained in previous studies, the lactose+skim 
milk protective mixture was used for the freeze-drying of free or encapsulated L. reuteri CRL 
1324 cells.  
When evaluating the survival of encapsulated L. reuteri CRL 1324 during the freeze-
drying process, bacterial viability was higher when the capsules were suspended previously in 
lactose+skim milk. In the case of encapsulated L. reuteri CRL 1324, the effect of 
lyoprotectors during drying could be explained, for example, by the formation of a protective 
cover with milk proteins over the xanthan-gellan capsules, thus providing a more compact 
physical barrier for the encapsulated cells (Gerez et al., 2012). 
On the other hand, the survival of encapsulated L. reuteri CRL 1324 cells during 
freeze-drying was significantly lower than cell suspensions with lyoprotectors. These results 
suggest that the xanthan-gellan polymeric mixture was efficient in the process of 
encapsulating microorganism, but failed to provide adequate protection against the stress 
caused by freeze-drying process. When comparing the survival during lyophilization of free 
and encapsulated L. reuteri cells, the effect of lyoprotectors decreased when the cells were 
encapsulated. The polymeric matrix probably caused a decrease in the interaction between 
lyoprotectors and bacterial cells included into capsules, compared to free microorganisms. In 
the protectors-cells interaction, milk proteins could form a protective cover directly over the 
cells, and carbohydrates could help to prevent or reduce the lethal effect of intracellular ice 
formation during freezing, through hydrogen bonds with water and cellular structures 
(stabilizing the cell membrane and proteins) (Santivarangkna et al., 2008). 
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Stability studies of L. reuteri CRL 1324 in xanthan-gellan capsules evidenced that no 
viable cells were obtained after a short time of storage (21-60 days) at room temperature (in 
lyophilized or nonlyophilized capsules) or at refrigerated temperature (only in nonlyophilized 
capsules). However, viability loss was minimal in freeze-dried free cells and freeze-dried 
encapsulated cells with lactose+skim milk. Carbohydrates could protect against free radicals 
produced during the storage and rehydration of freeze-dried cultures (Santivarangkna et al., 
2008). On the other hand, moisture content is critical to microbial viability during storage 
(Weinbreck et al., 2010). However, in this work the water content of the different systems 
under study was not determined during the stability testing period by technical limitations; in 
further studies, this parameter will be evaluated as a quality parameter. 
Systems constituted by xanthan-gellan capsules and free cell powders containing L. 
reuteri CRL 1324 (both freeze-dried with lactose+skim milk) were the optimal systems for 
storage at refrigerated temperature. Since L. reuteri CRL 1324 in xanthan-gellan capsules 
could be included in the design of a product for vaginal application, the release of bacterial 
cells in a medium similar to genital secretions was assayed. Results evidenced a marked 
release of microorganism in a short incubation time (3 h) at 37°C followed by a stable number 
of viable cells. Pliszczak et al. (2011) demonstrated that different commercial probiotic 
lactobacilli, which were included in microparticles of pectin and hyaluronic acid sodium salt, 
were released into MSVF in a sustained way during the first 10 h of incubation at 37°C, up to 
total release after 16 h. In contrast to our results, Pliszczak et al. (2011) observed bacterial 
proliferation after the complete release of encapsulated lactobacilli. 
The ability of microorganisms to maintain their viability and expression of beneficial 
characteristics during storage processes as well as stability in the conditions of the tract where 
will be applied are relevant properties that should be evaluated in each potential probiotic 
strain (du Toit et al., 2013; Domig et al., 2014). Free or encapsulated L. reuteri CRL 1324 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 19 
cells, freeze-dried and stored at refrigerated temperature, maintained both their ability to form 
biofilm and their antagonist activity against opportunist pathogenic S. agalactiae NH 17, two 
characteristics previously evidenced (Leccese et al., 2012; De Gregorio et al., 2014). On the 
other hand, L. reuteri CRL 1324 viability did not decrease significantly during 24 h of 
incubation in MSVF at 37°C and at a low pH (4.5). The survival of lyophilized cells in MSVF 
was higher than that of nonlyophilized fresh cultures, suggesting that the lactose+skim milk 
protective mixture or the xanthan-gellan polymeric cover of capsules could favor the survival 
of L. reuteri CRL 1324 under nonstandard conditions. In this work, the pH of MSVF assayed 
was similar to normal vaginal pH. Further experiments need to be performed to evaluate 
bacterial stability under different genital tract conditions (e.g. different pH conditions in the 
vaginal lumen in the case of genital infections and in the presence of semen) (Borges et al., 
2013). 
The systems selected (lyophilized powders and capsules) in this work could be used in 
appropriate pharmaceutical forms for vaginal application for the prevention and/or treatment 
of human female urogenital tract infections. The main advantage of these systems is the 
inclusion of dried bacterial cells, which is a critical point to preserve the stability of probiotic 
microorganisms (Weinbreck et al., 2010). Therefore, future incorporation of powders and 
capsules into vaginal solid forms with low water activity (e.g. capsules, tablets and ovules) 
will be carried out. Vaginal tablets and Witepsol® ovules including freeze-dried vaginal 
probiotic strains have been proved effective to preserve bacterial viability during storage for 
different periods (Borges et al., 2013; Muller et al., 2014; Verdenelli et al., 2014). On the 
contrary, in potential probiotic liquid formulations, marked viability losses were evidenced 
(Borges and Teixeira, 2014; Verdenelli et al., 2014).  
On the other hand, vaginal solid and semi-solid delivery forms allow obtaining a 
continuous release of active principles for several hours, unlike liquid formulations that 
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present a short residence time in vagina (Pliszczak et al., 2011). In this sense, mucoadhesive 
anionic polymers as xanthan and gellan used to encapsulate L. reuteri CRL 1324 could help 
and promote the permanence of the active ingredients in the vaginal mucosa. 
In conclusion, encapsulation (by extrusion-ionic gelation) and freeze-drying in the 
presence of lyoprotectors (lactose+skim milk) and their subsequent storage in refrigeration 
conditions favored the maintenance of vaginal L. reuteri CRL 1324 viability and ability to 
survive in MSVF, form biofilm and inhibit pathogenic S. agalactiae. Further studies should 
be performed to improve the survival of encapsulated L. reuteri CRL 1324 under adverse 
conditions during production industrial processes and subsequent storage and to evaluate the 
interaction of formulated systems with mucosa vaginal components. 
 
Acknowledgements 
This work was supported by CONICET (Consejo Nacional de Investigaciones Científicas y 
Técnicas, Argentina) (PIP 2012 N° 744) and ANPCyT (Agencia Nacional de Promoción 
Científica y Tecnológica) (PICT 2012-1187). L. reuteri CRL 1324 was licensed through a 
CONICET-BIOLIFE agreement. 
None of the authors have a conflict of interests for the publication of the manuscript. 
 
References 
Alli, A., 2011. Preparation and characterization of a coacervate extended-release 
microparticulate delivery system for Lactobacillus rhamnosus. Int. J. Nanomed. 6, 1699-
1707. 
Borges, S., Costa, P., Silva, J., Teixeira, P., 2013. Effects of processing and storage on 
Pediococcus pentosaceus SB83 in vaginal formulations: lyophilized powder and tablets. 
Biomed. Res. Int. 2013, 680767. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 21 
Borges, S., Teixeira, P., 2014. Pediococcus pentosaceus SB83 as a potential probiotic 
incorporated in a liquid system for vaginal delivery. Benefic Microbes. 5, 421-426. 
De Gregorio, P.R., Juárez Tomás, M.S., Leccese Terraf, M.C., Nader-Macias, M.E., 2014. In 
vitro and in vivo effects of beneficial vaginal lactobacilli on pathogens responsible for 
urogenital tract infections. J. Med. Microbiol. 63, 685-696. 
De Gregorio, P.R., Juárez Tomás, M.S., Leccese Terraf, M.C., Nader-Macías, M.E.F., 2015. 
Preventive effect of Lactobacillus reuteri CRL1324 on Group B Streptococcus vaginal 
colonization in an experimental mouse model, J. Appl. Microbiol. 118, 1034-1047. 
De Man, J.C., Rogosa, M., Sharpe, M.E., 1960. A medium for the cultivation of lactobacilli. 
J. Appl. Bacteriol. 23, 130-135. 
Ding, W.K., Shah, N.P., 2009. Effect of various encapsulating materials on the stability of 
probiotic bacteria. J. Food Sci. 74, 100-107. 
Domig, K.J., Kiss, H., Petricevic, L., Viernstein, H., Unger, F., Kneifel, W., 2014. Strategies 
for the evaluation and selection of potential vaginal probiotics from human sources: an 
exemplary study. Benef. Microbes. 5, 263-272. 
du Toit, E., Vesterlund, S., Gueimonde, M., Salminen, S., 2013. Assessment of the effect of 
stress-tolerance acquisition on some basic characteristics of specific probiotics. Int. J. Food 
Microbiol. 165, 51-56. 
Endo, A., Teräsjärvi, J., Salminen, S., 2014. Food matrices and cell conditions influence 
survival of Lactobacillus rhamnosus GG under heat stresses and during storage. Int. J. 
Food Microbiol. 174, 110-112. 
FAO/WHO, 2001. Evaluation of health and nutritional properties of powder milk and live 
lactic acid bacteria, Food and Agriculture Organization of the United Nations and World 
Health Organization Expert Consultation Report. 
http://www.fao.org/es/ESN/Probio/probio.htm 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 22 
Gerez, C.L., Font de Valdez, G., Gigante, M.L., Grosso, C.R.F., 2012. Whey protein coating 
bead improves the survival of the probiotic Lactobacillus rhamnosus CRL 1505 to low pH. 
Lett. Appl. Microbiol. 54, 552–556.  
Heckly, R.J., 1985. Principles of preserving bacteria by freeze-drying. Dev. Ind. Microbiol. 
25, 379-395. 
Hill, C., Guarner, F., Reid, G., Gibson, G.R. , Merenstein, D.J., Pot, B., Morelli, L., Canani, 
R.B., Flint, H.J., Salminen, S., Calder, P.C., Sanders, M.E., 2014. Expert consensus 
document: The International Scientific Association for Probiotics and Prebiotics consensus 
statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. 
Hepatol. 11, 506-514. 
Human Microbiome Project Consortium, 2012. Structure, function and diversity of the 
healthy human microbiome. Nature. 486, 207-214. 
Islam, M.A., Yun, C.H., Choi, Y.J., Cho, C.S., 2010. Microencapsulation of live probiotic 
bacteria. J. Microbiol. Biotechnol. 20, 1367-1377.  
Jiménez-Pranteda, M.L., Poncelet, D., Nader-Macías, M.E., Arcos, A., Aguilera, M., 
Monteoliva-Sánchez, M., Ramos-Cormenzana, A., 2012. Stability of lactobacilli 
encapsulated in various microbial polymers. J. Biosci. Bioeng. 113, 179-184. 
Juárez Tomás, M.S., Ocaña, V.S., Wiese, B., Nader-Macías, M.E., 2003. Growth and lactic 
acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of 
uropathogenic Escherichia coli, J. Med. Microbiol. 52, 1117-1124. 
Juárez Tomás, M.S., Bru, E., Martos, G., Nader-Macías, M.E., 2009. Stability of freeze-dried 
vaginal Lactobacillus strains in the presence of different lyoprotectors. Can. J. Microbiol. 
55, 544-552. 
Juárez Tomás, M.S., Nader-Macías, M.E., 2007. Effect of a medium simulating vaginal fluid 
on the growth and expression of beneficial characteristics of potentially probiotic 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 23 
lactobacilli, in: Méndez-Vilas, A. (Ed.), Communicating Current Research and Educational 
Topics and Trends in Applied Microbiology. Microbiology Book Series. Formatex, 
Badajoz, pp: 732-739. 
Juárez Tomás, M.S., Saralegui Duhart, C.I., De Gregorio, P.R., Vera Pingitore, E., Nader-
Macías, M.E., 2011. Urogenital pathogen inhibition and compatibility between vaginal 
Lactobacillus strains to be considered as probiotic candidates. Eur. J. Obstet. Gynecol. 
Reprod. Biol. 159, 399-406. 
Leccese Terraf, M.C., Juárez Tomás, M.S., Nader-Macías, M.E., Silva, C., 2012. Screening of 
biofilm formation by beneficial vaginal lactobacilli and influence of culture media 
components. J. Appl. Microbiol. 113, 1517-1529. 
Leccese Terraf, M.C., Mendoza, L.M., Juárez Tomás, M.S., Silva, C., Nader-Macías, M.E., 
2014. Phenotypic surface properties (aggregation, adhesion and biofilm formation) and 
presence of related genes in beneficial vaginal lactobacilli. J. Appl. Microbiol. 117, 1761-
1772. 
Martín Villena, M.J., Morales Hernández, M.E., Gallardo Lara, V., Ruiz Martínez, M.A., 
2009. Técnicas de microencapsulación: una propuesta para microencapsular probióticos. 
Ars. Pharm. 50, 43-50. 
Martín Villena, M.J., Morales Hernández, M.E., Gálvez Martín, P., Clares Naveros, B., Ruiz 
Martínez, M.A., 2010. Desarrollo de una técnica para la microencapsulación de 
probióticos. ARS Pharm. 51 Suppl 3, 479-484. 
Martos, G.I., Minahk, C.J., Font de Valdez, G., Morero, R., 2007. Effects of protective agents 
on membrane fluidity of freeze-dried Lactobacillus delbrueckii ssp. bulgaricus. Lett. Appl. 
Microbiol. 45, 282-288. 
Mastromarino, P., Vitali, B., Mosca, L., 2013. Bacterial vaginosis: a review on clinical trials 
with probiotics. New Microbiol. 36, 229-238. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 24 
Muller, C., Busignies, V., Mazel, V., Forestier, C., Nivoliez, A., Tchoreloff, P., 2013. 
Mechanistic approach to stability studies as a tool for the optimization and development of 
new products based on L. rhamnosus Lcr35® in compliance with current regulations. 
PLoS One. 8, e79041. 
Muller, C., Mazel, V., Dausset, C., Busignies, V., Bornes, S., Nivoliez, A., Tchoreloff, P., 
2014. Study of the Lactobacillus rhamnosus Lcr35® properties after compression and 
proposition of a model to predict tablet stability. Eur. J. Pharm. Biopharm. 88, 787-794. 
Ocaña, V.S., Bru, E., de Ruiz Holgado, A.P., Nader-Macías, M.E., 1999. Surface 
characteristics of lactobacilli isolated from human vagina. J. Gen. Appl. Microbiol. 45, 
203-212. 
Pliszczak, D., Bourgeois, S., Bordes, C., Valour, J.P., Mazoyer, M.A., Orecchioni, A.M., 
Nakache, E., Lantéri, P., 2011. Improvement of an encapsulation process for the 
preparation of pro- and prebiotics-loaded bioadhesive microparticles by using experimental 
design. Eur. J. Pharm. Sci. 44, 83-92.  
Raibaud, P., Galpin, J.V., Ducluzeau, R., Mocquot, G., Oliver, G., 1973. Le genre 
Lactobacillus dans le tuve digestif du rat. I. Caractères de souches homofermentaires 
isolées de rats Holo et Gnotoxéniques. Ann. Microbiol. (Paris). 124, 83-109. 
Reid, G., 2014. Modulating the vaginal microbiome: the need for a bridge between science 
and practice. Semin. Reprod. Med. 32, 28-34. 
Remuñán López, C., Alonso Fernández, M.J., 1997. Microencapsulación de medicamentos, 
in: Vila Jato, J.L. (Ed.), Tecnología farmacéutica. Volumen I: Aspectos fundamentales de 
los sistemas farmacéuticos y operaciones básicas. Síntesis SA, Madrid, pp. 577-609.  
Santivarangkna, C., Higl, B., Foerst, P., 2008. Protection mechanisms of sugars during 
different stages of preparationprocess of dried lactic acid starter cultures. Food Microbiol. 
25, 429-441. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 25 
Savini, M., Cecchini, C., Verdenelli, M.C., Silvi, S., Orpianesi, C., Cresci, A., 2010. Pilot-
scale production and viability analysis of freeze-dried probiotic bacteria using different 
protective agents. Nutrients. 2, 330-339.  
Solanki, H.K., Pawar, D.D., Shah, D.A., Prajapati, V.D., Jani, G.K., Mulla, A.M., Thakar, 
P.M., 2013. Development of microencapsulation delivery system for long-term 
preservation of probiotics as biotherapeutics agent. Biomed. Res. Int. 2013:620719.  
Sun, W., Griffiths, M.W., 2000. Survival of bifidobacteria in yogurt and simulated gastric 
juice following immobilization in gellan-xanthan beads. Int. J. Food Microbiol. 61, 17-25. 
Verdenelli, M.C., Coman, M.M., Cecchini, C., Silvi, S., Orpianesi, C., Cresci A., 2014. 
Evaluation of antipathogenic activity and adherence properties of human Lactobacillus 
strains for vaginal formulations. J. Appl. Microbiol. 116, 1297-1307. 
Weinbreck, F., Bodnár, I., Marco, M.L., 2010. Can encapsulation lengthen the shelf-life of 
probiotic bacteria in dry products? Int. J. Food Microbiol. 136, 364-367.  
Witkin, S.S., 2015. The vaginal microbiome, vaginal anti-microbial defense mechanisms and 
the clinical challenge of reducing infection-related preterm birth. BJOG. 122, 213-218. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 26 
Figure legends  
Fig. 1. Scheme summarizing the preparation and storage conditions of the different systems 
assayed in this work to preserve the stability of Lactobacillus reuteri CRL 1324. 
 
Fig. 2. Viability of Lactobacillus reuteri CRL 1324 during the lyophilization process. 
Different systems were freeze-dried: capsules in the presence of a lactose+skim milk 
protective mixture (Capsules with L-SM), capsules in the absence of protectors (Capsules 
without L-SM) and free cells in the presence of protectors (Free cells with L-SM). The data 
are plotted as the mean values of viable cells numbers (log CFU/g ± SEM). Different letters 
indicate statistically significant differences (P < 0.05) in the number of viable cells between 
the different systems subjected to lyophilization on the different times of process (Pre-FD, 
before freeze-drying; Post-FD, after freeze-drying), according to Tukey‟s test. 
 
Fig. 3. Main effects of condition, temperature and time on Lactobacillus reuteri CRL 1324 
survival during the storage process for 150 days. In the “Condition” panel, each point 
indicates the mean value of log CFU/ml for each condition at all storage times and 
temperatures. In the “Temperature” panel, each point indicates the mean value of log 
CFU/ml for each temperature, at all storage times and conditions. In the “Time” panel, each 
point indicates the mean value of log CFU/g for each time at all conditions and temperatures. 
Conditions (systems) in which bacterial cells were stored: freeze-dried capsules in the 
presence of lactose-skim milk protective mixture (FD cap. with L-SM); freeze-dried capsules 
in the absence of protectors (FD cap. without L-SM), nonlyophilized capsules (Non FD cap.) 
and freeze-dried free cells in the presence of protectors (FD free cells with L-SM). In each 
panel, different letters indicate statistically significant differences (P < 0.05) in the mean 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 27 
values of log CFU/g between the levels of the factor assayed (condition, temperature or 
storage time), according to Tukey‟s test. 
 
Fig. 4. Viability of Lactobacillus reuteri CRL 1324 during storage for 150 days at room 
temperature (a) and refrigeration (4°C) temperature (b). Conditions (systems) in which 
bacterial cells were stored: (-■-) freeze-dried capsules in the presence of lactose+skim milk 
protective mixture; (- -) freeze-dried capsules in the absence of protectors, (-♦-) 
nonlyophilized capsules; (-▲-) freeze-dried free cells in the presence of protectors. The data 
are plotted as the mean values of viable cell numbers (log CFU/g ± SEM). Different letters 
indicate statistically significant differences (P < 0.05) in the number of viable cells between 
the different conditions and storage times at a same temperature, according to Tukey‟s test. 
 
Fig. 5. Scanning electronic microscopy of xanthan-gellan capsules containing Lactobacillus 
reuteri CRL 1324 that were freeze-dried in the presence of lactose+skim milk protective 
mixture. a-b) Whole capsules observed at 90x. c-d) Capsule section with microorganisms 
included in a polymeric matrix, observed at 3000x and 10000x. 
 
Fig. 6. Release rate in a medium similar to vaginal fluid and potential beneficial properties of 
Lactobacillus reuteri CRL 1324. a) Release rate of L. reuteri CRL 1324 from freeze-dried 
capsules in the presence of lactose+skim milk protective mixture, incubated in a medium 
similar to vaginal fluid (MSVF) at 37°C for 24 h. Release rate was calculated as Nt/Ni, where 
Nt is the log CFU/g at incubation time “t” and Ni is the log CFU/g at initial incubation time. 
Data are plotted as the mean values of release rates ± SEM. b) Mixed and pure cultures of L. 
reuteri CRL 1324 (CRL 1324) and S. agalactiae NH 17 (NH 17). Data are plotted as the 
mean values of viable cell numbers (log CFU/ml ± SEM) of CRL 1324 and NH 17 at 24 h of 
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incubation at 37°C in LAPTg broth. Different letters indicate statistically significant 
differences (P < 0.05) in the number of viable cells for each microorganism in pure and mixed 
cultures, according to Tukey‟s test. c) Biofilm formation from freeze-dried encapsulated cells 
(FD capsules), freeze-dried free cells (FD free cells) and fresh free cells (Fresh culture) of L. 
reuteri CRL 1324 after 72 h of incubation at 37°C in MRS without Tween 80. The data 
express the mean OD570 nm values ± SEM of acetic acid-solubilized crystal violet-stained 
cultures from polystyrene microplates. Different letters indicate significant differences (P < 
0.05) in biofilm formation between the different conditions assayed, according to Tukey‟s 
test. The results of panels a), b) and c) correspond to systems stored for 150 days; similar 
results were obtained during all storage periods. 
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